To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with a study in familial early-onset disease in Colombia, and it has yet another amyloid antibody (gantenerumab) in the pipeline, but crenezumab itself for Alzheimer's in the general population appears to have failed.
You may be wondering about your own memory by this point - it's hard to keep track, but